LFCR Stock Forecast & Price Target

Lifecore Biomedical has demonstrated solid operational momentum, marked by a 9.8% growth in the latest quarter, which underscores the company’s ongoing efforts to enhance its visibility as a contract development and manufacturing partner. The significant capacity utilization target of 60% by 2029, up from 20% in 2025, reflects optimism about ramping developmental revenue and the anticipated impact of new commercial agreements, suggesting a robust outlook for future profitability. As these factors align with a projected revenue compound annual growth rate (CAGR) of 12% leading up to 2029, Lifecore Biomedical is well-positioned for substantial growth over the next several years.

Lifecore Biomedical has experienced a significant decline in share price of over 50% in the last two months, primarily attributed to disappointing financial guidance for FY/26 and conservative projections for FY/27, signaling potential stagnation in revenue growth. The company reported a decrease in CDMO revenue, driven by a loss of take-or-pay revenue and lower sales volumes, which were only partially offset by increased developmental revenue; additionally, FY guidance indicates a $17 million to $18 million revenue headwind from factors such as customer loss, inventory adjustments, and delayed product launches. Concerns about the need for a potential capital raise further exacerbate the negative outlook, highlighting the financial strain the company may face moving forward.